


## m-PEG11-acid

<b>Cat. No.:</b>	HY-140501
<b>CAS No.:</b>	2280998-74-3
<b>Molecular Formula:</b>	C <sub>24</sub> H <sub>48</sub> O <sub>13</sub>
<b>Molecular Weight:</b>	544.63
<b>Target:</b>	ADC Linker; PROTAC Linkers
<b>Pathway:</b>	Antibody-drug Conjugate/ADC Related; PROTAC
<b>Storage:</b>	-20°C, protect from light, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (183.61 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	1.8361 mL	9.1805 mL	18.3611 mL
	5 mM	0.3672 mL	1.8361 mL	3.6722 mL
	10 mM	0.1836 mL	0.9181 mL	1.8361 mL

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

<b>Description</b>	m-PEG11-acid is a non-cleavable 11 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs) <sup>[1]</sup> . m-PEG11-acid is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs <sup>[2]</sup> .	
<b>IC<sub>50</sub> &amp; Target</b>	PEGs	Non-cleavable Linker
<b>In Vitro</b>	ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker <sup>[1]</sup> . PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

### REFERENCES

[1]. Wilfried Braje et al. Macrocyclic mcl-1 inhibitors and methods of use. WO2019035927A1.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA